Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 26;7(2):e22483.
doi: 10.2196/22483.

Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic

Bernardo Pereira Cabral #  1   2 , Luiza Braga #  2   3 , Fabio Mota #  2
Affiliations

Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic

Bernardo Pereira Cabral et al. JMIR Public Health Surveill. .

Abstract

Background: The COVID-19 pandemic presents a great public health challenge worldwide, especially given the urgent need to identify effective drugs and develop a vaccine in a short period of time. Globally, several drugs and vaccine candidates are in clinical trials. However, because these drugs and vaccines are still being tested, there is still no definition of which ones will succeed.

Objective: This study aimed to assess the opinions of over 1000 virus researchers with knowledge on the prevention and treatment of coronavirus-related human diseases to determine the most promising drug and vaccine candidates to address COVID-19.

Methods: We mapped the clinical trials related to COVID-19 registered at ClinicalTrials.gov. These data were used to prepare a survey questionnaire about treatments and vaccine candidates for COVID-19. In May 2020, a global survey was conducted with authors of recent scientific publications indexed in the Web of Science Core Collection related to viruses, severe acute respiratory syndrome coronavirus, coronaviruses, and COVID-19.

Results: Remdesivir, immunoglobulin from cured patients, and plasma were considered to be the most promising treatments in May 2020, while ChAdOx1 and mRNA-1273 were considered to be the most promising vaccine candidates. Almost two-thirds of the respondents (766/1219, 62.8%) believed that vaccines for COVID-19 were likely to be available in the next 18 months. Slightly fewer than 25% (289/1219, 23.7%) believed that a vaccine was feasible, but probably not within 18 months.

Conclusions: The issues addressed in this study are constantly evolving; therefore, the current state of knowledge has changed since the survey was conducted. However, for several months after the survey, the respondents' expectations were in line with recent results related to treatments and vaccine candidates for COVID-19.

Keywords: COVID-19; SARS-CoV-2; clinical trial; drug; public health; survey; treatment; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Research design used in the study. MeSH: Medical Subject Headings; WoS: Web of Science.
Figure 2
Figure 2
Demographic overview of the survey respondents.
Figure 3
Figure 3
Survey respondents’ expectations regarding whether a vaccine for COVID-19 will be available in the next 18 months, and their choices of the most promising vaccine candidates.
Figure 4
Figure 4
Therapeutics chosen by the respondents to be most likely to succeed in treating COVID-19. § Umifenovir (0.69%); ¢ Unknown antimalarial (0.20%); ª Mefloquine (0.10%); + Chloroquine (0.10%); $ Other antibiotic (0.10%); * Losartan (0.10%); º Captopril (0.10%); @ Bevacizumab (0.20%); £ Acalabrutinib (0.10%); # Other kinase inhibitor (0.10%); ¬ Other nondrug (0.10%).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) J Gen Intern Med. 2020 May 4;35(5):1545–1549. doi: 10.1007/s11606-020-05762-w. http://europepmc.org/abstract/MED/32133578 - DOI - PMC - PubMed
    1. WHO timeline - COVID-19. World Health Organization. [2020-05-23]. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19.
    1. Coronavirus disease (COVID-19) pandemic. World Health Organization. [2020-05-23]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. World Health Organization. 2020. Mar 13, [2021-02-19]. https://www.who.int/docs/default-source/coronaviruse/clinical-management....
    1. COVID 19 landscape of experimental treatments. World Health Organization. [2021-02-19]. https://www.who.int/publications/i/item/covid-19-landscape-of-experiment....

Substances